Ultragenyx Pharmaceutical Inc 2026年季度报告

OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.For the transition period fromto.Commission File No. 001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware(State or other jurisdiction of incorporation or organization) 27-2546083 (I.R.S. Employer Identification No.) 60 Leveroni CourtNovato, California(Address of principal executive offices) (415) 483-8800(Registrant’s telephone number, including area code) (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) hasfiled all reports required to befiled by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile suchreports), and (2) has been subject to suchfiling requirements for the past 90 days.YES☑NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit suchfiles).YES☑NO☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smallerreporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☑Non-acceleratedfiler☐ Acceleratedfiler☐Smaller reporting company☐Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☑ As of May 1, 2026, the registrant had 98,489,224 shares of common stock issued and outstanding. ULTRAGENYX PHARMACEUTICAL INC. INDEX PageCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS1Part I –Financial InformationItem 1.Financial StatementsCondensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Comprehensive Loss5Condensed Consolidated Statements of Stockholders’ Equity (Deficit)6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk31Item 4.Controls and Procedures32Part II –Other InformationItem 1.Legal Proceedings33Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds69Item 3.Defaults Upon Senior Securities69Item 4.Mine Safety Disclosures69Item 5.Other Information69Item 6.Exhibits70Signatures71 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or the Quarterly Report, contains forward-looking statements that involve risks anduncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities LitigationReform Act of 1995 and other federal securities laws. All statements other than statements of historical fact contained in thisQuarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as"aim," “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,”“project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words, or other comparable terminology. Theseforward-looking statements include, but are not limited to, statements about: •our commercialization, marketing, and manufacturing capabilities and strategy;•our expectations regarding the timing of clinical study commencements and reporting results from same;•the timing and likelihood of regulatory approvals for, or commercialization of, our product candidates;•the anticipated indications for our product candidates, if approved;•the potential market opportunities for commercializing our products and product candidates;•our expectations regarding the potential market size and the size of the patient populations for our products and productcandidates, if approved for commercial use;•estimates of our expenses, revenue, capital requirements, and our needs for additionalfinancing;•our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical studies;•the outcome of the FDA’s review of our resubmitted Biologics License Application, or BLA, for UX111, includin